- 中国生物製薬（1177） 増資決定
sino biopharmaceutical (01177) intends to raise up to $619.75 million from top-up placing.the company has agreed to place as many as 185 million shares through a placing agent on a best effort basis at a price of $3.35 per share, sino biopharmaceutical said in a statement. trading in the stock will be resumed this morning.the net proceeds of $603.06million will be used to finance future possible acquisitions as and when appropriate opportunities arise.the placing price of $3.35 per share represents a discount of approximately 8.97% to the last trading price of $3.68 per share. the placing shares represent approximately 3.73% of the enlarged issued share capital of the company.中国生物製薬(1177)は新株1億8500万株の発行で約6億2000万香港ドルの増資を発表
- China stock index futures open lower Thursday
China's stock index futures opened lower Thursday, with the contract for settlement in August, the most actively traded, opened at 2,740, down 4.4 points from the previous trading.
The September contract opened at 2,758.6, unchanged from the previous trading while the December contract opened at 2,789.4, down 1.4 points from the previous trading.
The stock-index contracts, agreements to buy or sell the Hushen 300 Index at a present value on an agreed date, are designed to allow investors t ... 中国の株価指数先物は8月にオープン反落での決済契約を結んで、最も活発に取引取引前のオープンで2740、下4.4ポイントから9月の契約はオープンで開か2,758.6、契約は変更されませんから12月以前の取引中1.4ポイントから以前の取引停止で2,789.4、在庫ありインデックスの契約、契約書を購入したりした日の値に合意した現在のインデックスを300販売ハッシェンは、t投資家ができるようにしているように設計...
- Trading halt on BC Iron, Regent
Shares of Australia's BC Iron and its second-biggest shareholder, Regent Pacific, Group were placed on trading halts yesterday amid speculation Hong Kong-based Regent would make a US$300 million takeover bid for the iron ore miner.
グループでは、投機香港ベースのリージェントの中で昨日の取引停止に置かれたオーストラリアのBC鉄とその第2位の株主、リージェントパシフィックの株式は、米国に鉄鉱石鉱山3億ドルの買収になるだろう
|
